Status:
COMPLETED
AZD3355 Dose-escalation Study in Healthy Males
Lead Sponsor:
AstraZeneca
Conditions:
Reflux Disease
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The aim is to establish the maximal tolerated dose of AZD3355 for the selection of doses in the up-coming studies. This will be done by comparing single and repeated doses of AZD3355 to placebo ("inac...
Eligibility Criteria
Inclusion
- Subjects without concurrent diseases who do not require any medical treatments
- Provision of signed informed consent.
Exclusion
- History of somatic disease/condition, which may interfere with the objectives for the study, as judged by the investigator.
- Clinically significant illness or clinically relevant trauma within the 2 weeks prior to the administration of the investigational product, as judged by the investigator.
- History of clinically significant orthostatic reaction or syncope
- Clinically important abnormalities related to the heart function
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00757419
Start Date
September 1 2008
End Date
December 1 2008
Last Update
December 7 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Gothenburg, Sweden